Giuseppe Lassandro

Dr. Giuseppe Lassandro


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
GLGiuseppe Lassandro
Giuseppe Lassandro
MCMariangela Chiarito
Mariangela Chiarito
FVFederica Valente
Federica Valente
LCLoredana Ciaccia
Loredana Ciaccia
Paola GiordanoPaola Giordano
Paola Giordano
Bone remodeling is a lifelong process, due to the balanced activity of the osteoblasts (OBs), the bone-forming cells, and osteoclasts (OCs), the bone-resorbing cells. This equilibrium is mainly regulated by the WNT-ß-cathenin pathway and the RANK-RANKL/OPG system, respectively. Bone ageing is a process which normally occurs during life due to the imbalance between bone formation and bone resorption, potentially leading to osteoporosis. Bone loss associated with bone ageing is determined by oxidative stress, the result of the increasing production of reactive oxygen species (ROS). The promotion of physical exercise during growth increases the chances of accruing bone and delaying the onset of osteoporosis. Several studies demonstrate that physical exercise is associated with higher bone mineral density and lower fracture incidence, and the resulting bone mineral gain is maintained with ageing, despite a reduction of physical activity in adulthood. The benefits of exercise are widely recognized, thus physical activity is considered the best non-pharmacologic treatment for pathologies such as osteoporosis, obesity, diabetes and cardiovascular disease. We reviewed the physiological mechanisms which control bone remodeling, the effects of physical activity on bone health, and studies on the impact of exercise in reducing bone ageing.

GLGiuseppe Lassandro
Giuseppe Lassandro
VPViviana Valeria Palmieri
Viviana Valeria Palmieri
VPValentina Palladino
Valentina Palladino
AAAnna Amoruso
Anna Amoruso
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
Paola GiordanoPaola Giordano
Paola Giordano
Venous thromboembolism (VTE) in children is a rare occurrence, although in recent decades we have seen an increase due to several factors, such as the rise in survival of subjects with chronic conditions, the use of catheters, and the increased sensitivity of diagnostic tools. Besides inherited thrombophilia, acquired conditions such as cardiovascular diseases, infections, chronic disorders, obesity and malignancy are also common risk factors for paediatric VTE. The treatment of paediatric VTE consists of the use of heparins and/or vitamin K antagonists to prevent dissemination, embolization, and secondary VTE. Randomized clinical trials of direct oral anticoagulants in paediatric VTE are ongoing, with the aim to improve the compliance and the care of patients. We reviewed the physiological and pathological mechanisms underlying paediatric thrombosis and updated the current diagnosis and treatment options.

Paola GiordanoPaola Giordano
Paola Giordano
FUFLAVIA URBANO
FLAVIA URBANO
GLGiuseppe Lassandro
Giuseppe Lassandro
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
Sickle bone disease (SBD) is a chronic and invalidating complication of Sickle cell disease (SCD), a multisystem autosomal recessive genetic disorder affecting millions of people worldwide. Mechanisms involved in SBD are not completely known, especially in pediatric age. Among the hypothesized pathogenetic mechanisms underlying SBD are bone marrow compensatory hyperplasia and bone ischemic damage, both secondary to vaso-occlusive crisis (VOC), which leads to cell sickling, thus worsening local hypoxia with a negative impact on osteoblast recruitment. Furthermore, the hypoxia is a strong activator of erythropoietin, which in turn stimulates osteoclast precursors and induces bone loss. Hemolysis and iron overload due to a chronic transfusion regimen could also contribute to the onset of bone complications. Vitamin D deficiency, which is frequently seen in SCD subjects, may worsen SBD by increasing the resorptive state that is responsible for low bone mineral density, acute/chronic bone pain, and high fracture risk. An imbalance between osteoblasts and osteoclasts, with a relative decrease of osteoblast recruitment and activity, is a further possible mechanism responsible for the impairment of bone health in SCD. Moreover, delayed pubertal growth spurt and low peak bone mass may explain the high incidence of fracture in SCD adolescents. The aim of this review was to focus on the pathogenesis of SBD, updating the studies on biochemical, instrumental, and biological markers of bone metabolism. We also evaluated the growth development and endocrine complications in subjects affected with SCD.

30 September 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
Paola GiordanoPaola Giordano
Paola Giordano
FUFLAVIA URBANO
FLAVIA URBANO
GLGiuseppe Lassandro
Giuseppe Lassandro
FBFrancesco Paolo Bianchi
Francesco Paolo Bianchi
ATAlessandra Tolva
Alessandra Tolva
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza

5 May 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Paola GiordanoPaola Giordano
Paola Giordano
GBGiacomina Brunetti
Giacomina Brunetti
GLGiuseppe Lassandro
Giuseppe Lassandro
LNLucia D. Notarangelo
Lucia D. Notarangelo
MLMatteo Luciani
Matteo Luciani
Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza

Maria Felicia FaienzaMaria Felicia Faienza
Maria Felicia Faienza
FUFLAVIA URBANO
FLAVIA URBANO
GLGiuseppe Lassandro
Giuseppe Lassandro
FVFederica Valente
Federica Valente
GDGabriele D’amato
Gabriele D’amato
Paola GiordanoPaola Giordano
Paola Giordano
The risk of developing cardiovascular diseases (CVDs) arises from the interaction of prenatal factors; epigenetic regulation; neonatal factors; and factors that affect childhood and adolescence, such as early adiposity rebound (AR) and social and environmental influences. Thus, CVD risk varies between the group of low-risk metabolically healthy normal-weight subjects (MHNW); the intermediate-risk group, which includes metabolically healthy obese (MHO) and metabolically unhealthy normal-weight subjects (MUHNW); and the high-risk group of metabolically unhealthy obese (MUHO) subjects. In this continuum, several risk factors come into play and contribute to endothelial damage, vascular and myocardial remodeling, and atherosclerotic processes. These pathologies can occur both in prenatal life and in early childhood and contribute to significantly increasing CVD risk in young adults over time. Early intervention in the pediatric MUHO population to reduce the CVD risk during adulthood remains a challenge. In this review, we focus on CVD risk factors arising at different stages of life by performing a search of the recent literature. It is urgent to focus on preventive or early therapeutic strategies to stop this disturbing negative metabolic trend, which manifests as a continuum from prenatal life to adulthood.